.jpg)
Dangerous Drug Will Carry Warning
The drug, Phenergan became a household word when Diana Levine’s fight against drug maker, Wyeth, went all the way to the U.S. Supreme Court.
Levine complained that the drug label did not explicitly warn against administering it via the IV push method.
Now it will.
The Food and Drug Administration (FDA) has ordered the companies that make Phenergan, (now generically sold by other companies as promethazine hydrochloride), to slap a “black box” warning on the drug to tell the public the nausea-reliever should not be delivered via an IV push, a method to more quickly deliver the drug into the bloodstream.
Levine wishes it had been there all along.
“I’m thrilled,” she said in a phone interview with the Philadelphia Inquirer, though she wishes ithe FDA ordered an outright ban instead of indicating that the preferred method of administering is through intramuscular injection.
Had the warning been on the label in the spring of 2000, she might not have lost her right arm.
In 2000, Levine had a migraine headache and went to a local clinic in Marshfield, Vermont to be treated.
Because the drug she was given also gave her nausea, she was administered Phenergan via an IV push, also known as intravenous push, method.
The clinician accidentally penetrated her artery with the needle. The drug caused her right arm to be infected with gangrene.
Eventually doctors had to amputate, a devastating injury for a musician who uses her right arm to pay the guitar and make music, her livelihood.
Levine sued the clinic but also Wyeth for failing to adequately warn the public in its label.
At a lower court trial, Levine’s jurors agreed that the drug should have carried a warning against IV push method and awarded her $7 million. But Wyeth argued that federal preemption, or approval by the FDA, shielded the company from product liability lawsuits.
The outcome of this trial would determine whether Americans retained their rights to hold drug makers liable and was closely watched by many.
In March 2009, the high court struck a blow to Wyeth and to supporters of federal preemption. Levine’s lower court ruling stood.
But she told IB News she would rather have her arm.
FDA’s Karen Riley says since the IV method requires such low doses, it would effectively eliminate IV push as an alternative, reports the Philadelphia Inquirer. #